GET DAILY SIGNALSCronos Group (CRON) Reports +75% Revenue Jump and Record EBITDA in Q3
Key Takeaways
- Net revenue climbed 75% year over year to $63.45 million, comfortably above the $49.47 million consensus estimate.
- Earnings per share (EPS) came in at $0.04, beating the $0.025 analyst estimate.
- Adjusted EBITDA reached a record $17.1 million, up 201% from $5.7 million a year earlier.
- Gross margin held near 50.9%, while operating income swung to a $9.0 million profit from a $0.5 million loss in the prior-year quarter.
- GAAP net income fell 37% to $17.8 million, reflecting a prior-year foreign-exchange gain and tax benefit rather than weaker operations.
- The company ended the quarter with roughly $841 million in cash and investments, supporting its buyback and growth plans.
Why This Quarter Matters
Cronos Group’s third-quarter results stand out because they demonstrate the cannabis producer turning rising sales into real operating profits. After several years of losses, the company has now delivered consecutive quarters of revenue growth and posted its highest adjusted EBITDA on record. I’m watching closely to see whether momentum in Canada, Israel, and Germany can offset softer demand elsewhere while keeping gross margins steady. With a strong cash position and an ongoing share repurchase program, CRON has the resources to support expansion and potential acquisitions.
Quarterly Results in Detail
Net revenue reached $63.45 million, a 75% increase from $36.34 million in the same quarter last year and above consensus estimates. Earnings per share of $0.04 topped the $0.025 analyst forecast. Gross profit rose 76% to $32.3 million, with the margin at 50.9%. Operating income moved to a $9.0 million profit from a $0.5 million loss previously. Adjusted EBITDA hit $17.1 million, up from $5.7 million, helped by higher gross profit. Operating expenses grew 23% year over year but dropped to 37% of revenue from 52%, showing better leverage. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
GAAP net income declined 37% to $17.8 million, mainly because the prior-year period included a foreign-exchange gain and tax benefit that did not recur. The company finished the quarter with about $841 million in cash and short-term investments and generated positive operating cash flow through the first nine months of 2026.
Stock Reaction and Investor Views
Shares rose after the release, supported by the revenue and earnings beat that reinforced confidence in the operating turnaround. The stock had already climbed notably in the months before the report, leaving it well above longer-term moving averages. Sentiment stays cautiously optimistic. Bulls highlight record revenue, expanding margins, and a balance sheet that can fund buybacks and deals. Bears point to the year-over-year GAAP earnings drop, the lack of a forward margin target, and slower growth in Israel amid an ongoing anti-dumping investigation.
What to Watch Going Forward
Several factors will shape results in coming quarters. Gross margin sustainability remains important, as management noted that margins can vary with seasonality, product mix, and pricing pressure. International growth, especially in Germany after the CanAdelaar acquisition, will influence top-line momentum. Potential headwinds include price compression in Germany, seasonal softness in Canadian purchasing, and regulatory uncertainty in Israel. The balance sheet and capital-return strategy also merit attention, given the cash position and active buyback program.
Using AI Tools in My Research
When analyzing earnings like these, I often turn to Tickeron’s AI Screener to quickly compare CRON against peers on fundamentals, technical signals, and performance metrics. It helps surface relevant trade ideas and monitor how the broader sector is behaving without manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRON's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CRON turned positive on October 21, 2026. Looking at past instances where CRON's MACD turned positive, the stock continued to rise in 52 of 58 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CRON as a result. In 89 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
CRON moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CRON crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Following a +5.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in 169 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for CRON moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 18 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 55 cases where CRON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
CRON broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.210) is normal, around the industry mean (7.659). P/E Ratio (18.474) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (6.993) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
pharmaceutical, medical marijuana, cannabis
Industry PharmaceuticalsGeneric
Advertisement